Kardium
Kardium is a Canadian medical device company that develops the Globe Pulsed Field System, an integrated cardiac mapping and ablation platform using a 122-electrode catheter to treat atrial fibrillation, sold directly to hospitals and electrophysiology centers.
- Company typePrivate
- Founded2007
- HeadquartersBurnaby, Canada
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Kardium does
Kardium is a privately held Canadian medical device company founded in 2007 and headquartered in Burnaby, British Columbia, that develops the Globe Pulsed Field System for the diagnosis and treatment of atrial fibrillation. The system integrates high-density cardiac mapping and pulsed field ablation in a single 122-electrode spherical array catheter, enabling true single-shot pulmonary vein isolation with proprietary GlobePulse waveform energy, real-time thermal contact sensing, and the optional Globe Positioning System (GPS) 3D navigation module. The PULSAR IDE pivotal trial of 183 patients across 12 international centers demonstrated 78% 12-month freedom from atrial arrhythmia, 0% device-related primary safety events, and 100% acute procedural success, supporting FDA Pre-Market Approval received in September 2025.
Kardium sells the Globe System directly to hospitals and electrophysiology centers through an enterprise field sales motion. The company holds a CE Mark for European sales (since June 2020) and operates Kardium GmbH in Dortmund, Germany, as its European commercial subsidiary. Following FDA PMA in September 2025, the company launched commercially in the United States in October 2025 with first procedures at St. Bernards Medical Center. The company has grown to nearly 600 employees (tripled from approximately 200 in 2022) and has raised approximately US$469M cumulatively across multiple rounds led by T. Rowe Price, Fidelity Management & Research, Janus Henderson Investors, Qatar Investment Authority, and others, with a stated intention to prepare for a potential IPO under CFO Koert VandenEnden. The intellectual property portfolio includes over 600 patents across the US, France, Germany, Great Britain, China, and India.
The company serves two primary segments: hospitals and electrophysiology centers performing catheter ablation procedures, and patients with paroxysmal or persistent atrial fibrillation, a condition affecting more than 8 million people in the US and nearly 50 million worldwide. Revenue is generated through hardware sales of the catheter, introducer sheath, generator, and mapping software sold via direct enterprise sales under multi-year hospital contracts with undisclosed unit pricing. Competitive positioning is anchored on integrated single-catheter mapping and ablation, 122-electrode architecture, and the safety profile of non-thermal pulsed field energy versus incumbent thermal ablation modalities.
Kardium firmographics
Firmographics- Name
- Kardium
- Legal name
- Kardium Inc.
- Website
- https://kardium.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Kardium is a Canadian medical device company that develops the Globe Pulsed Field System, an integrated cardiac mapping and ablation platform using a 122-electrode catheter to treat atrial fibrillation, sold directly to hospitals and electrophysiology centers.
- Ownership category
- akta.pro rank
Kardium industry classification
Industry- Product category
- Cardiac Electrophysiology Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Electrophysiology Mapping & Ablation Systems (HLAHAFAD)
- akta.pro secondary industry
- Electrophysiology (Heart Rhythm) (HLAKABAC)
Keywords
Where Kardium is headquartered
LocationHeadquarters
- HQ city
- Burnaby
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
Kardium business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Globe Pulsed Field System Device Sales: Sale of the Globe Pulsed Field System including the Globe Catheter (122-electrode spherical array), Globe Introducer sheath, Globe Mapping Software, and Globe PF Generator. Sold directly to hospitals and electrophysiology centers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Globe Pulsed Field System — medical device (no public pricing) |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Kardium product offering
Product offeringCore offering
Kardium develops and manufactures the Globe Pulsed Field System, an integrated cardiac mapping and ablation platform that combines a 122-electrode spherical array catheter with proprietary software and a pulsed field ablation generator to perform high-density mapping, pulmonary vein isolation, and customizable atrial ablation in a single device. The system is sold directly to hospitals and electrophysiology centers for the catheter-based treatment of atrial fibrillation. A legacy radiofrequency (RF) version, the Globe Mapping and Ablation System, is also commercially available in Europe.
Product overview
Kardium offers the Globe Pulsed Field System as its primary commercial product, consisting of multiple integrated components: the Globe Catheter (a 122-electrode spherical array), the Globe PF Generator, the Globe Introducer sheath, and proprietary Globe Mapping Software. The system uniquely combines high-density cardiac mapping and pulsed field ablation (PFA) in a single catheter, enabling single-shot pulmonary vein isolation with real-time thermal contact sensing. The company also offers the Globe Positioning System (GPS) as a 3D mapping and navigation add-on module. A legacy radiofrequency (RF) version (Globe Mapping and Ablation System) remains available in Europe. The portfolio centers on treating atrial fibrillation through integrated mapping and ablation technology.
Differentiator
Problem solved
Functional benefit
Products and services
- Globe Pulsed Field System Integrated cardiac mapping and pulsed field ablation (PFA) system combining high-density mapping and ablation in a single 122-electrode spherical array catheter. FDA-approved (PMA, September 2025) for the treatment of paroxysmal atrial fibrillation; enables single-shot pulmonary vein isolation, customizable circumferential, linear, focal, and area lesion sets, and real-time thermal contact sensing without catheter exchanges. Sold directly to hospitals and electrophysiology centers.
- Globe Mapping and Ablation System (RF) Earlier version of the Globe System using radiofrequency (RF) energy for ablation, featuring the same 122-electrode spherical array catheter for high-density mapping and RF ablation. CE-marked and commercially available in Europe via Kardium GmbH (Dortmund, Germany).
Quantifiable outcome
- 78% 12-month freedom from atrial arrhythmia in paroxysmal AF patients (PULSAR IDE pivotal trial, n=183)
- +7 more outcomes
Companies that use Kardium
Customer profileNamed customers7 records
Segments2 records
Ideal customer profiles1 record
Kardium technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Kardium partnerships and signals
Strategic signalScale indicators8 records
Recent moves6 records
Expansion highlights6 records
Kardium competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights7 records
Customer concentration
Kardium social profiles
Digital presenceKardium compliance and trust
Trust signalCompliance5 records
Kardium financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kardium leadership team
Management profileNumber of profiles
Profiles13 records
Kardium subsidiaries and ownership
Company hierarchySubsidiaries1 record
Kardium funding detail
Funding detailFunding overview
Funding rounds9 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kardium M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kardium
What does Kardium do?
Kardium develops and manufactures the Globe Pulsed Field System, an integrated cardiac mapping and ablation platform that combines a 122-electrode spherical array catheter with proprietary software and a pulsed field ablation generator to perform high-density mapping, pulmonary vein isolation, and customizable atrial ablation in a single device. The system is sold directly to hospitals and electrophysiology centers for the catheter-based treatment of atrial fibrillation. A legacy radiofrequency (RF) version, the Globe Mapping and Ablation System, is also commercially available in Europe.
Is Kardium a public or private company?
Kardium is a private company. It is classified as venture growth investor backed and is currently operating.
When was Kardium founded?
Kardium was founded in 2007. It employs 251 to 500 people.
Where is Kardium based?
Kardium is headquartered in Burnaby, Canada, in the North America region.
How does Kardium make money?
One revenue line is on record: globe Pulsed Field System Device Sales.
Does Kardium have an API?
No public API is recorded for Kardium.
What industry is Kardium in?
Kardium's product category is Cardiac Electrophysiology Devices. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAKABAC, Electrophysiology (Heart Rhythm). Its NAICS code is 334510 and its SIC code is 3841.